Douglas A Rubinson

List of Publications by Year
in descending order

40 papers	5,332 citations	196777 29 h-index	371746 37 g-index
42 all docs	42 docs citations	42 times ranked	9590 citing authors

#	Article	IF	Citations
1	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist, 2022, 27, 292-298.	1.9	2
2	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. BMJ Open Sport and Exercise Medicine, 2022, 8, e001353.	1.4	2
3	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 1069-1081.	3.2	75
4	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discovery, 2021, 11, 2014-2031.	7.7	79
5	FGFR2Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery, 2021, 11, 2488-2505.	7.7	46
6	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology, 2021, 21, 1119-1126.	0.5	13
7	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. , 2021, 9, e002472.		13
8	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell, 2021, 184, 6119-6137.e26.	13.5	201
9	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. Journal of Gastrointestinal Oncology, 2021, 12, 3133-3140.	0.6	2
10	Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers, 2020, 12, 3451.	1.7	6
11	Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncology, 2020, 6, e202948.	3.4	72
12	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1586-1595.	1.1	8
13	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 2019, 21, 213-223.	1.1	151
14	Effect of High-Dose vs Standard-Dose Vitamin D₃ Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2019, 321, 1370.	3.8	134
15	Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2018, 16, 1300-1306.e3.	2.4	21
16	Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2018, 4, e173420.	3.4	155
17	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discovery, 2018, 8, 1096-1111.	7.7	256
18	Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. British Journal of Cancer, 2017, 117, 1874-1882.	2.9	73

#	Article	IF	Citations
19	Cigarette Smoking and Pancreatic Cancer Survival. Journal of Clinical Oncology, 2017, 35, 1822-1828.	0.8	78
20	Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine. , 2017, , .		3
21	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Journal of Clinical Oncology, 2016, 34, 2899-2905.	0.8	49
22	Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Journal of the National Cancer Institute, 2016, 108, djv409.	3.0	31
23	Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus. Journal of Clinical Oncology, 2015, 33, 29-35.	0.8	83
24	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 761-776.	0.9	11
25	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. Oncologist, 2015, 20, 499-507.	1.9	64
26	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. Oncologist, 2014, 19, 637-638.	1.9	292
27	Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Investigational New Drugs, 2014, 32, 113-122.	1.2	42
28	Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nature Medicine, 2014, 20, 1193-1198.	15.2	510
29	Prediagnostic Body Mass Index and Pancreatic Cancer Survival. Journal of Clinical Oncology, 2013, 31, 4229-4234.	0.8	115
30	Ena/VASP is required for endothelial barrier function in vivo. Journal of Cell Biology, 2007, 179, 761-775.	2.3	103
31	Ena/VASP Is Required for Neuritogenesis in the Developing Cortex. Neuron, 2007, 56, 441-455.	3.8	204
32	Filopodia are required for cortical neurite initiation. Nature Cell Biology, 2007, 9, 1347-1359.	4.6	276
33	Ena/VASP is required for endothelial barrier function in vivo. Journal of Experimental Medicine, 2007, 204, i26-i26.	4.2	0
34	RNAI AS AN EXPERIMENTAL AND THERAPEUTIC TOOL TO STUDY AND REGULATE PHYSIOLOGICAL AND DISEASE PROCESSES. Annual Review of Physiology, 2005, 67, 147-173.	5.6	96
35	Lamellipodin, an Ena/VASP Ligand, Is Implicated in the Regulation of Lamellipodial Dynamics. Developmental Cell, 2004, 7, 571-583.	3.1	301
36	A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genetics, 2003, 33, 401-406.	9.4	1,427

#	Article	IF	Citations
37	A La protein requirement for efficient pre-tRNA folding. EMBO Journal, 2003, 22, 6562-6572.	3.5	99
38	ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16865-16870.	3.3	42
39	Critical Roles of Phosphorylation and Actin Binding Motifs, but Not the Central Proline-rich Region, for Ena/Vasodilator-stimulated Phosphoprotein (VASP) Function during Cell Migration. Molecular Biology of the Cell, 2002, 13, 2533-2546.	0.9	117
40	ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos. Current Biology, 2002, 12, 159-163.	1.8	70